CalciMedica, Inc. (CALC)

NCM – Real vaqt narxi. Valyuta: USD

0.63

+0.04 (6.63%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.63

-0.00 (-0.59%)

Bozor oldidan: May 13, 2026, 4:06 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

CalciMedica, Inc. (CALC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CalciMedica, Inc. (CALC)

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Videolar

No Data

Press-relizlar

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Search stocks

CalciMedica, Inc. (CALC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

CalciMedica, Inc. (CALC)

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Videolar

No Data

Press-relizlar

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates